What is CJC-1295 / Ipamorelin?
A commercial research blend combining a CJC-1295-type GHRH analogue with the growth-hormone secretagogue Ipamorelin for GH-axis laboratory study.
What researchers study
- Growth-hormone axis signaling
- GHRH and GHS pathway interaction
- Endocrine research
- Recovery and metabolic physiology models
Administration, dosing & shelf-life context
The blend is sold for laboratory research only. No human reconstitution, injection, timing, or cycling instructions are provided.
No established male human dose is provided for this research blend.
No established female human dose is provided for this research blend.
The seller does not publish a validated time-based shelf life on the current listing. Follow the lot expiry/BUD and COA.
Follow seller label/COA conditions and avoid repeated freeze-thaw cycles if the product is reconstituted for legitimate laboratory work.
Research comparison ideas
These are literature/comparator ideas, not a recommendation to combine or co-administer compounds.
- No additional stack is suggested; the product is already a multi-compound research blend
- Ipamorelin and CJC-1295 No DAC single-agent pages can be used as comparator references
Evidence boundary
Combination-product effects cannot be assumed from evidence on either component alone. This blend is not an approved therapeutic formulation.
Research-use boundary: This educational profile does not diagnose, treat, prescribe, calculate doses, or provide a self-experimentation protocol.